HUTCHMED (China) Limited
HCM.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.06 | -0.24 | -0.10 | -0.75 |
| FCF Yield | -0.69% | 6.10% | -12.07% | -3.89% |
| EV / EBITDA | 174.71 | 42.57 | -5.59 | -16.65 |
| Quality | ||||
| ROIC | -3.70% | 1.93% | -59.97% | -32.35% |
| Gross Margin | 44.64% | 18.08% | 27.04% | 27.49% |
| Cash Conversion Ratio | 0.01 | 2.17 | 0.75 | 1.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 13.91% | 33.01% | 23.21% | 20.23% |
| Free Cash Flow Growth | -109.34% | 161.14% | -38.14% | -170.66% |
| Safety | ||||
| Net Debt / EBITDA | -4.55 | -2.94 | 0.71 | 1.05 |
| Interest Coverage | -14.14 | 24.21 | -625.30 | -554.59 |
| Efficiency | ||||
| Inventory Turnover | 6.92 | 13.66 | 5.49 | 7.22 |
| Cash Conversion Cycle | 105.40 | 58.32 | 66.95 | 78.00 |